Robert Zerbe Biography and Net Worth

Chairman & Director of Vericel

Dr. Robert Zerbe joined the Vericel Board of Directors in January 2006 and has been its Chairman since October 2012. Until July 2016, Dr. Zerbe served as the Chief Executive Officer of QUATRx Pharmaceuticals Company, a venture?backed drug development company, which he co?founded in 2000. Prior to his role at QUATRx, Dr. Zerbe held several senior executive management positions with major pharmaceutical companies, including Eli Lilly and Company and Pfizer. During his tenure at Eli Lilly, Dr. Zerbe’s clinical research and development positions included Managing Director, Lilly Research Center U.K., and Vice President of Clinical Investigation and Regulatory Affairs. He joined Parke?Davis in 1993, becoming Senior Vice President of Worldwide Clinical Research and Development. In this capacity, Dr. Zerbe led the clinical development programs for a number of key products, including Lipitor^® and Neurontin^®. Dr. Zerbe received his M.D. from the Indiana University School of Medicine and he has completed post?doctoral work in internal medicine, endocrinology and neuroendocrinology at Indiana University and the National Institutes of Health. Dr. Zerbe serves on the boards of directors of Metabolic Solutions Development Company and Cirius Therapeutics, both private companies focusing on metabolic diseases.

What is Robert L. Zerbe's net worth?: The estimated net worth of Robert L. Zerbe is at least $1.09 million as of February 5th, 2025. Dr. Zerbe owns 26,595 shares of Vericel stock worth more than $1,086,938 as of April 22nd. This net worth evaluation does not reflect any other investments that Dr. Zerbe may own. Learn More about Robert L. Zerbe's net worth.
How do I contact Robert L. Zerbe?: The corporate mailing address for Dr. Zerbe and other Vericel executives is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. Vericel can also be reached via phone at (617) 588-5555 and via email at ir@vcel.com. Learn More on Robert L. Zerbe's contact information.
Has Robert L. Zerbe been buying or selling shares of Vericel?: Robert L. Zerbe has not been actively trading shares of Vericel during the past quarter. Most recently, Robert L. Md Zerbe sold 2,500 shares of the business's stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $62.50, for a transaction totalling $156,250.00. Following the completion of the sale, the director now directly owns 26,595 shares of the company's stock, valued at $1,662,187.50. Learn More on Robert L. Zerbe's trading history.
Who are Vericel's active insiders?: Vericel's insider roster includes Dominick Colangelo (President & CEO), Sean Flynn (VP), Steven Gilman (Director), Michael Halpin (COO), Jonathan Hopper (Insider), Joseph Mara, Jr. (CFO), Jonathan Siegal (Vice President & Corporate Controller), Paul Wotton (Director), and Robert Zerbe (Chairman & Director). Learn More on Vericel's active insiders.
Are insiders buying or selling shares of Vericel?: During the last year, insiders at the biotechnology company sold shares 18 times. They sold a total of 166,999 shares worth more than $7,916,453.29. The most recent insider tranaction occured on April, 10th when CEO Dominick Colangelo sold 24,850 shares worth more than $1,040,966.50. Insiders at Vericel own 5.2% of the company. Learn More about insider trades at Vericel.
Information on this page was last updated on 4/10/2025.

Robert L. Zerbe Insider Trading History at Vericel

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/5/2025	Sell	2,500	$62.50	$156,250.00	26,595
11/22/2024	Sell	2,500	$60.00	$150,000.00	26,595
3/27/2024	Sell	3,278	$51.57	$169,046.46	23,395
1/29/2024	Sell	2,300	$44.22	$101,706.00	23,395
1/25/2024	Sell	200	$44.02	$8,804.00	25,695
1/22/2024	Sell	8,000	$41.85	$334,800.00	25,895
1/12/2024	Sell	2,200	$38.09	$83,798.00	30,895
7/14/2023	Sell	1,000	$38.84	$38,840.00	33,395
6/22/2023	Sell	3,000	$36.00	$108,000.00	34,395
11/23/2020	Sell	17,500	$23.55	$412,125.00	34,295

Robert L. Zerbe Buying and Selling Activity at Vericel

Vericel Company Overview

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $40.87

$40.31

$41.75

50 Day Range

MA: $47.12

$38.60

$57.78

2 Week Range

Now: $40.87

$37.76

$63.00

Volume

532,733 shs

Average Volume

390,036 shs

Market Capitalization

$2.05 billion

P/E Ratio

681.28

Dividend Yield

N/A

Beta

1.61